IPO - Amylyx Pharmaceuticals, Inc.

Form Type: 424B5

Filing Date: 2025-01-10

Corporate Action: Ipo

Type: New

Accession Number: 000119312525004002

Filing Summary: Amylyx Pharmaceuticals, Inc. filed a preliminary prospectus supplement related to the offering of shares of its common stock, for which the registration statement is effective with the SEC. The company seeks to raise capital to advance its commercialization efforts and pipeline programs targeting serious diseases. Their stock is listed under the symbol 'AMLX' on Nasdaq, with a closing price of $3.77 as of January 8, 2025. The offering includes a public offering price and provisions for underwriter discounts and commissions, as well as options for additional shares. The filing reveals risks associated with investing in the securities, including potential dilution of shares and market volatility. Amylyx is identified as a smaller reporting company, granting it reduced public disclosure obligations. Key products in development include avexitide for various hypoglycemia conditions and AMX0035 for neurodegenerative diseases such as ALS and Wolfram Syndrome.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-01-10

Corporate Action: Ipo

Type: New

Accession Number: 000119312525004537

Filing Summary: Amylyx Pharmaceuticals, Inc. is offering 17,142,857 shares of common stock at a public offering price of $3.50 per share, aiming to raise approximately $60 million. The pricing indicates a recent closing share value of $3.77 on January 8, 2025. The company intends to utilize the net proceeds for commercialization preparations, pipeline programs, working capital, and general corporate purposes. Underwriters, led by Leerink Partners, have a 30-day option to purchase an additional 2,571,428 shares. As a smaller reporting company, Amylyx is subject to reduced public reporting requirements and recognizes significant associated investment risks. Notably, they are engaged in the development of therapies for serious health conditions, including treatments for neurodegenerative diseases and metabolic disorders.

Document Link: View Document